News | December 10, 2025
Novo Nordisk completes acquisition of Akero Therapeutics
Akero became a wholly owned subsidiary of Novo Nordisk
Akero became a wholly owned subsidiary of Novo Nordisk
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
_256_384.jpg)
Tirzepatide is the first and only dual agonist glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Captured microbes are then neutralized on engineered microbicidal surfaces
While Merck can appeal, Halozyme said it expects the order to hold
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Subscribe To Our Newsletter & Stay Updated
